This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Susan E. Molchan, MD
National Institute of Mental Health NIH Clinical Center 9000 Rockville Pike, Bldg 10, Rm 3D-41 Bethesda, MD 20892

Benedetto Vitiello, MD; Marcia Minichiello, MA; Trey Sunderland, MD
Bethesda, Md

Arch Gen Psychiatry. 1991;48(12):1113-1114.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The role of the cholinergic system in neuropsychiatric disease has been the topic of two recent articles in the ARCHIVES.^1,2 The cognitive and behavioral effects of the cholinesterase inhibitor physostigmine salicylate in patients with Alzheimer's disease has been the subject of an ongoing study. We describe the fluctuation in one patient's psychotic and depressive symptoms that were consistent with the hypotheses that associate increased muscarinic activity with depressive and negative symptoms. The patient's psychotic symptoms were alleviated, although the depressive symptoms increased with physostigmine treatment. This agent presumably increases the functional activity of acetylcholine and causes a relative decrease in dopaminergic activity (as reflected by a decrease in cerebrospinal fluid homovanillic acid). This fluctuation of symptoms and biochemical profile suggests certain parallels to patients with schizophrenia, in whom increased muscarinic activity has been associated with depressive and negative symptoms, and increased mesocorticolimbic dopaminergic activity with psychosis.¹ . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?